Rezu¯m System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Validation of Convective Thermal Energy Transfer and Characterization with Magnetic Resonance Imaging and 3-Dimensional Renderings

Lance A. Mynderse, Dennis Hanson, Richard A. Robb, Dalibor Pacik, Viteslav Vit, Gabriel Varga, Lennart Wagrell, Magnus Tornblom, Edwin Rijo Cedano, David A Woodrum, Christopher M. Dixon, Thayne R. Larson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective To evaluate by magnetic resonance imaging the physical effects of convective thermal energy transfer with water vapor as a means of treating lower urinary tract symptoms due to benign prostatic hyperplasia. Methods Sixty-five men with lower urinary tract symptoms were treated with the Rezu¯m System by transurethral intraprostatic injection of water vapor. A group of 45 of these men consented to undergo a series of gadolinium-enhanced magnetic resonance imagings of the prostate after treatment to monitor the size and location of ablative lesions, their time course of resolution, and the corresponding change in prostate tissue volume. Visualization was conducted at 1 week, 1, 3, and 6 months after treatment. Results Outcomes were available for 44 patients. Convective thermal lesions were limited to the transition zone and correlated with targeted treatment locations. At 1 week after treatment, the mean volume of ablative lesions was 8.2 cm<sup>3</sup> (0.5-24.0 cm<sup>3</sup>). At 6 months, whole prostate volume was reduced by a mean of 28.9% and transition zone volume by 38.0% as compared with baseline 1-week images. At 3 and 6 months after treatment, the lesion volumes had reduced by 91.5% and 95.1%, respectively. Lesions remained within the targeted treatment zone without compromising integrity of the bladder, rectum, or striated urinary sphincter. Conclusion This imaging study confirms the delivery of convective water vapor technology to create thermal lesions in the prostate tissue. Lesions generated underwent near complete resolution by 3 and 6 months after treatment with a concomitant one-third reduction in overall prostate and transition zone volumes.

Original languageEnglish (US)
Pages (from-to)122-127
Number of pages6
JournalUrology
Volume86
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Lower Urinary Tract Symptoms
Energy Transfer
Steam
Prostatic Hyperplasia
Hot Temperature
Magnetic Resonance Imaging
Prostate
Therapeutics
Gadolinium
Rectum
Urinary Bladder
Technology
Injections

ASJC Scopus subject areas

  • Urology

Cite this

Rezu¯m System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia : Validation of Convective Thermal Energy Transfer and Characterization with Magnetic Resonance Imaging and 3-Dimensional Renderings. / Mynderse, Lance A.; Hanson, Dennis; Robb, Richard A.; Pacik, Dalibor; Vit, Viteslav; Varga, Gabriel; Wagrell, Lennart; Tornblom, Magnus; Cedano, Edwin Rijo; Woodrum, David A; Dixon, Christopher M.; Larson, Thayne R.

In: Urology, Vol. 86, No. 1, 01.07.2015, p. 122-127.

Research output: Contribution to journalArticle

Mynderse, Lance A. ; Hanson, Dennis ; Robb, Richard A. ; Pacik, Dalibor ; Vit, Viteslav ; Varga, Gabriel ; Wagrell, Lennart ; Tornblom, Magnus ; Cedano, Edwin Rijo ; Woodrum, David A ; Dixon, Christopher M. ; Larson, Thayne R. / Rezu¯m System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia : Validation of Convective Thermal Energy Transfer and Characterization with Magnetic Resonance Imaging and 3-Dimensional Renderings. In: Urology. 2015 ; Vol. 86, No. 1. pp. 122-127.
@article{a2c2c871e12a4ababf5418ed7e1c47f4,
title = "Rezu¯m System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Validation of Convective Thermal Energy Transfer and Characterization with Magnetic Resonance Imaging and 3-Dimensional Renderings",
abstract = "Objective To evaluate by magnetic resonance imaging the physical effects of convective thermal energy transfer with water vapor as a means of treating lower urinary tract symptoms due to benign prostatic hyperplasia. Methods Sixty-five men with lower urinary tract symptoms were treated with the Rezu¯m System by transurethral intraprostatic injection of water vapor. A group of 45 of these men consented to undergo a series of gadolinium-enhanced magnetic resonance imagings of the prostate after treatment to monitor the size and location of ablative lesions, their time course of resolution, and the corresponding change in prostate tissue volume. Visualization was conducted at 1 week, 1, 3, and 6 months after treatment. Results Outcomes were available for 44 patients. Convective thermal lesions were limited to the transition zone and correlated with targeted treatment locations. At 1 week after treatment, the mean volume of ablative lesions was 8.2 cm3 (0.5-24.0 cm3). At 6 months, whole prostate volume was reduced by a mean of 28.9{\%} and transition zone volume by 38.0{\%} as compared with baseline 1-week images. At 3 and 6 months after treatment, the lesion volumes had reduced by 91.5{\%} and 95.1{\%}, respectively. Lesions remained within the targeted treatment zone without compromising integrity of the bladder, rectum, or striated urinary sphincter. Conclusion This imaging study confirms the delivery of convective water vapor technology to create thermal lesions in the prostate tissue. Lesions generated underwent near complete resolution by 3 and 6 months after treatment with a concomitant one-third reduction in overall prostate and transition zone volumes.",
author = "Mynderse, {Lance A.} and Dennis Hanson and Robb, {Richard A.} and Dalibor Pacik and Viteslav Vit and Gabriel Varga and Lennart Wagrell and Magnus Tornblom and Cedano, {Edwin Rijo} and Woodrum, {David A} and Dixon, {Christopher M.} and Larson, {Thayne R.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.urology.2015.03.021",
language = "English (US)",
volume = "86",
pages = "122--127",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Rezu¯m System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia

T2 - Validation of Convective Thermal Energy Transfer and Characterization with Magnetic Resonance Imaging and 3-Dimensional Renderings

AU - Mynderse, Lance A.

AU - Hanson, Dennis

AU - Robb, Richard A.

AU - Pacik, Dalibor

AU - Vit, Viteslav

AU - Varga, Gabriel

AU - Wagrell, Lennart

AU - Tornblom, Magnus

AU - Cedano, Edwin Rijo

AU - Woodrum, David A

AU - Dixon, Christopher M.

AU - Larson, Thayne R.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Objective To evaluate by magnetic resonance imaging the physical effects of convective thermal energy transfer with water vapor as a means of treating lower urinary tract symptoms due to benign prostatic hyperplasia. Methods Sixty-five men with lower urinary tract symptoms were treated with the Rezu¯m System by transurethral intraprostatic injection of water vapor. A group of 45 of these men consented to undergo a series of gadolinium-enhanced magnetic resonance imagings of the prostate after treatment to monitor the size and location of ablative lesions, their time course of resolution, and the corresponding change in prostate tissue volume. Visualization was conducted at 1 week, 1, 3, and 6 months after treatment. Results Outcomes were available for 44 patients. Convective thermal lesions were limited to the transition zone and correlated with targeted treatment locations. At 1 week after treatment, the mean volume of ablative lesions was 8.2 cm3 (0.5-24.0 cm3). At 6 months, whole prostate volume was reduced by a mean of 28.9% and transition zone volume by 38.0% as compared with baseline 1-week images. At 3 and 6 months after treatment, the lesion volumes had reduced by 91.5% and 95.1%, respectively. Lesions remained within the targeted treatment zone without compromising integrity of the bladder, rectum, or striated urinary sphincter. Conclusion This imaging study confirms the delivery of convective water vapor technology to create thermal lesions in the prostate tissue. Lesions generated underwent near complete resolution by 3 and 6 months after treatment with a concomitant one-third reduction in overall prostate and transition zone volumes.

AB - Objective To evaluate by magnetic resonance imaging the physical effects of convective thermal energy transfer with water vapor as a means of treating lower urinary tract symptoms due to benign prostatic hyperplasia. Methods Sixty-five men with lower urinary tract symptoms were treated with the Rezu¯m System by transurethral intraprostatic injection of water vapor. A group of 45 of these men consented to undergo a series of gadolinium-enhanced magnetic resonance imagings of the prostate after treatment to monitor the size and location of ablative lesions, their time course of resolution, and the corresponding change in prostate tissue volume. Visualization was conducted at 1 week, 1, 3, and 6 months after treatment. Results Outcomes were available for 44 patients. Convective thermal lesions were limited to the transition zone and correlated with targeted treatment locations. At 1 week after treatment, the mean volume of ablative lesions was 8.2 cm3 (0.5-24.0 cm3). At 6 months, whole prostate volume was reduced by a mean of 28.9% and transition zone volume by 38.0% as compared with baseline 1-week images. At 3 and 6 months after treatment, the lesion volumes had reduced by 91.5% and 95.1%, respectively. Lesions remained within the targeted treatment zone without compromising integrity of the bladder, rectum, or striated urinary sphincter. Conclusion This imaging study confirms the delivery of convective water vapor technology to create thermal lesions in the prostate tissue. Lesions generated underwent near complete resolution by 3 and 6 months after treatment with a concomitant one-third reduction in overall prostate and transition zone volumes.

UR - http://www.scopus.com/inward/record.url?scp=84937428410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937428410&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2015.03.021

DO - 10.1016/j.urology.2015.03.021

M3 - Article

C2 - 25987496

AN - SCOPUS:84937428410

VL - 86

SP - 122

EP - 127

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -